Intraocular VEGF antagonists have been recently used to treat severe ROP, but they have possible systemic anti-angiogenic side effects that are detrimental to the development of other organs, such as the lung and brain, and they do not correct retinal neuronal injury8. The gene discussed is VEGFA; the disease is retinopathy of prematurity.